Please provide your email address to receive an email when new articles are posted on . The phase 3 High-Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) trial also demonstrated that ...

Adding a high dose of erythropoietin to therapeutic hypothermia did not reduce rates of death or disability in infants with neonatal hypoxic ischemic encephalopathy (HIE), a phase III randomized trial ...

Inadequate hemodialysis was a major cause of erythropoietin resistance in pediatric patients. Investigators have identified several risk factors associated with erythropoietin (EPO) resistance in ...

Erythropoietin is a vital hormone that stimulates the bone marrow to create red blood cells in the body. Having too much or too little erythropoietin in the body may contribute to problems with the ...

Erythropoietin was no help for newborns with hypoxic-ischemic encephalopathy already undergoing therapeutic hypothermia in the phase III HEAL trial. Combined death or neurodevelopmental impairment by ...

In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...

A 65-year-old woman with fourth stage CKD was admitted to a hospital in Wales with a week-long history of shortness of breath and fatigue. A 53-year-old man on home haemodialysis was found to have a ...